**Core tip:** The National Comprehensive Cancer Network clinical practice guidelines do not recommend palliative surgery for metastatic colorectal adenocarcinoma (CRA). Using the Surveillance Epidemiology and End Results database, we found that patients with M1a diseases had a significant survival benefit compared to those with M1b diseases and patients with M1a (lung metastasis) got best long-term outcomes with median overall survival prolonged by 15 mo compared with those without surgical treatment. These findings provide further evidence to support the use of palliative surgical procedure to treat metastatic CRA and develop effective individualized treatment strategy.

INTRODUCTION
============

Colorectal cancer (CRC) is one of the three most common malignancies with 135430 individuals expected to be diagnosed in 2017 in the United States\[[@B1]\]. However, approximately 20% of new CRC patients are diagnosed with distant-stage tumors, resulting in poor long-term outcomes with a 5-year survival rate of 23.2%\[[@B2]\].

Surgical resection is regarded as the only potentially curative treatment option for this disease and could significantly improve the prognosis of patients with metastatic CRC\[[@B3]\]. Rees et al\[[@B4]\] reported that the 5-year cancer-specific survival (CSS) rate for metastatic CRC patients undergoing primary and hepatic resection was 36%. Abdalla et al\[[@B5]\] showed that patients receiving surgical resection of primary tumors and liver metastases had a 5-year survival rate of up to 58%. Similarly, curative surgical treatment could increase the 5-year survival rate of 32% to 68% in CRC patients with resectable lung metastasis\[[@B6],[@B7]\]. Unfortunately, only one-fifth to one-quarter of metastatic CRC patients can receive curative surgical treatment\[[@B8]\], indicating that metastatic CRC patients are a heterogenous population.

According to the 8^th^ edition of American Joint Committee on Cancer (AJCC) tumor-node-metastasis staging system, metastatic CRC are classified into M1a (metastasis confined to one organ or site) and M1b (metastases in more than one organ/site or the peritoneum). Complete resection is impossible for most metastatic CRC patients (especially for those with M1b diseases) even after neoadjuvant chemoradiation. The National Comprehensive Cancer Network clinical practice guidelines\[[@B9]\] do not recommend palliative surgery unless there is a risk of significant acute bleeding, obstruction, perforation, or other severe symptoms based on comprehensive analysis of the literature\[[@B10]-[@B12]\]. However, accumulating evidence has shown that palliative surgery is associated with more favorable outcomes. For example, a pooled analysis including four randomized trials reported that patients receiving palliative primary tumor removal had prolonged overall survival (OS) compared with those not receiving operation\[[@B13]\]. Another population-based retrospective study reviewing 37793 metastatic CRC patients showed that palliative surgery was significantly related to better OS and CSS\[[@B14]\]. Finally, a systematic review consisting of 21 studies indicated that there was a survival benefit for palliative surgery in patients with metastatic CRC and criteria for palliative surgery should be extended on the basis of World Health Organization (WHO) performance status (PS) or tumor burden\[[@B15]\].

However, to our best knowledge, no studies have classified stage IV into subsets to assess the role of palliative surgery. Adenocarcinoma is the most common pathological type of CRC, accounting for approximately 90% of cases\[[@B16]\]. Thus, we subdivided colorectal adenocarcinoma (CRA) patient populations with stage IV disease on the basis of comorbidities from the Surveillance, Epidemiology, and End Results (SEER) database into stage IVA (M1a diseases) and stage IVB (M1b diseases). Outcomes of palliative surgery were then independently assessed.

MATERIALS AND METHODS
=====================

Patient source
--------------

Patient data, originating between 2010 and 2015, was collected from the SEER database, one of the largest cancer databases in the world\[[@B14]\]. The selection criteria were as follows: (1) Patients 18 years old or older; (2) Disease histologically diagnosed as adenocarcinoma; (3) Treated for first primary tumor; (4) Definite M1a or M1b diseases according to the 8^th^ edition of AJCC staging system; (5) No surgery for metastatic sites (including distant lymph nodes); (6) Surgical procedure or no surgical procedure to primary tumor (excluding tumor destruction or no pathologic specimen or unknown whether there was a pathologic specimen); and (7) Active follow-up. Cases with unknown survival time, status, or those coded as 0 mo were excluded. The entire cohort was divided into two groups based on the median age and calculation result of X-tile program (Yale University, 3.6.1, [Supplementary Figure 1](Supplementary Figure 1)). After propensity score matching (PSM), 2935 patients with M1a diseases and 2145 patients with M1b diseases were excluded owing to a lack of counterpart propensity scores. In survival analysis for M1a (liver metastasis) and M1a (lung metastasis), 2202 and 267 patients were further excluded, respectively. Follow-up time ranged from 1 to 71 mo.

Statistical analyses
--------------------

Baseline characteristics of metastatic CRA patients, including sex, year of diagnosis, age, marital status, primary site, surgical information, race, grade, chemotherapy, and radiotherapy, were recorded and analyzed by *χ^2^* test. The patient prognosis was assessed using univariate and multivariate Cox regression analyses with hazard ratios and 95% confidence intervals. To minimize potential selection bias, 1:1 PSM without replacement was used to investigate the effect of palliative primary tumor resection on metastatic CRA. After PSM adjustment, Kaplan-Meier method was employed to analyze the OS for M1a and M1b patients. All statistical analyses were conducted using IBM SPSS Statistics 22.0. *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

Baseline characteristics
------------------------

A total of 19680 patients with metastatic CRA were collected from the SEER database, which included 10399 cases of M1a diseases and 9281 cases of M1b diseases (Table [1](#T1){ref-type="table"}). The entire cohort consisted of 11107 (56.4%) males and 8573 (43.6%) females with a median age of 63 years (ranging from 18 to 108). Most patients were of White ethnicity (74.8%) and more than half of them had well or moderately differentiated tumors (grade I + II). Next, 15476 (78.6%) cases of primary tumors were located in the colon and 4204 (21.4%) in the rectum. The prevalence of metastatic CRA between 2010 and 2012 was similar to that between 2013 and 2015. However, M1b diseases seemed to account for a larger proportion from 48.4% during 2010-2012 to 51.6% during 2013-2015 while M1a diseases showed the opposite prevalence trend.

###### 

Baseline characteristics of metastatic colorectal adenocarcinoma patients

  **Variable**                               **Total (*n* = 19680) (%)**   **M1a (*n* = 10399) (%)**   **M1b (*n* = 9281) (%)**   ***P* value[1](#T1FN1){ref-type="table-fn"}**
  ------------------------------------------ ----------------------------- --------------------------- -------------------------- -----------------------------------------------
  Gender                                                                                                                          
  Female                                     8573 (43.6)                   4462 (42.9)                 4111 (44.3)                0.050
  Male                                       11107 (56.4)                  5937 (57.1)                 5170 (55.7)                
  Year of diagnosis                                                                                                               \< 0.001
  2010-2012                                  9835 (50.0)                   5342 (51.4)                 4493 (48.4)                
  2013-2015                                  9845 (50.0)                   5057 (48.6)                 4788 (51.6)                
  Age (years)                                                                                                                     \< 0.001
  \< 65                                      10680 (54.3)                  5507 (53.0)                 5173 (55.7)                
  ≥ 65                                       9000 (45.7)                   4892 (47.0)                 4108 (44.3)                
  Race                                                                                                                            0.011
  White                                      14715 (74.8)                  7856 (75.5)                 6859 (73.9)                
  Black                                      3033 (15.4)                   1578 (15.2)                 1455 (15.7)                
  Others                                     1932 (9.8)                    965 (9.3)                   967 (10.4)                 
  Marital status                                                                                                                  0.661
  Married                                    9774 (49.7)                   5180 (49.8)                 4594 (49.5)                
  Others                                     9906 (50.3)                   5219 (50.2)                 4687 (50.5)                
  Primary site                                                                                                                    0.027
  Colon                                      15476 (78.6)                  8114 (78.0)                 7362 (79.3)                
  Rectum                                     4204 (21.4)                   2285 (22.0)                 1919 (20.7)                
  Grade                                                                                                                           \< 0.001
  I + II[2](#T1FN2){ref-type="table-fn"}     11321 (57.5)                  6525 (62.7)                 4796 (51.7)                
  III + IV[3](#T1FN3){ref-type="table-fn"}   3889 (19.8)                   1909 (18.4)                 1980 (21.3)                
  Others                                     4470 (22.7)                   1965 (18.9)                 2505 (27.0)                
  Surgery                                                                                                                         \< 0.001
  Yes                                        9360 (47.6)                   5787 (55.6)                 3573 (38.5)                
  No                                         10320 (52.4)                  4612 (44.4)                 5708 (61.5)                
  Chemotherapy                                                                                                                    0.415
  Yes                                        14057 (71.4)                  7402 (71.2)                 6655 (71.7)                
  No/unknown                                 5623 (28.6)                   2997 (28.8)                 2626 (28.3)                
  Radiotherapy                                                                                                                    
  Yes                                        975 (5.0)                     670 (6.4)                   305 (3.3)                  \< 0.001
  No                                         18705 (95.0)                  9729 (93.6)                 8976 (96.7)                

*χ*^2^ test.

Well or moderately differentiated tumors.

Poorly differentiated or undifferentiated tumors.

Of the entire cohort, 14057 (71.4%) metastatic CRA patients received chemotherapy and 975 (5.0%) received radiotherapy; 9360 (47.6%) metastatic CRA patients received palliative primary tumor resection while 10320 (52.4%) did not. The proportion of patients with M1a diseases undergoing surgical procedure was much higher than that of M1b diseases (55.6% for M1a and 38.5% for M1b).

Survival analysis
-----------------

Univariate and multivariate Cox regression analyses for OS for both M1a and M1b patients were performed (Table [2](#T2){ref-type="table"}). The common independent prognostic factors in both M1a and M1b patients included year of diagnosis (2010-2012 *vs* 2013-2015), age (\< 65 *vs* ≥ 65), race (white *vs* black), marital status (married *vs* others), primary site (colon *vs* rectum), grade (I + II *vs* III + IV), surgery (yes *vs* no), and chemotherapy (yes *vs* no/unknown). Radiotherapy (yes *vs* no) was an independent prognostic factor for M1a patients but not for M1b patients.

###### 

Univariate and multivariate cox regression analyses for overall survival of metastatic colorectal adenocarcinoma patients

                      **M1a**               **M1b**                                                                                            
  ------------------- --------------------- ---------- --------------------- ---------- --------------------- ---------- --------------------- ----------
  Gender                                                                                                                                       
  Female              Reference                        Reference                        Reference                        Reference             
  Male                1.100 (1.054-1.147)   \< 0.001   1.025 (0.975-1.077)   0.339      1.043 (1.002-1.086)   0.042      1.020 (0.972-1.070)   0.428
  Year of diagnosis                                                                                                                            
  2010-2012           Reference                        Reference                        Reference                        Reference             
  2013-2015           0.972 (0.929-1.016)   0.208      0.981 (0.929-1.036)   0.486      0.965 (0.925-1.006)   0.096      0.972 (0.924-1.023)   0.277
  Age (years)                                                                                                                                  
  \< 65               Reference                        Reference                        Reference                        Reference             
  ≥ 65                1.675 (1.606-1.746)   \< 0.001   1.413 (1.344-1.485)   \< 0.001   1.527 (1.466-1.589)   \< 0.001   1.319 (1.256-1.385)   \< 0.001
  Race                                                                                                                                         
  White               Reference                        Reference                        Reference                        Reference             
  Black               1.138 (1.075-1.206)   \< 0.001   1.114 (1.042-1.192)   0.002      1.127 (1.068-1.191)   \< 0.001   1.137 (1.064-1.215)   \< 0.001
  Others              0.910 (0.844-0.981)   0.013      0.864 (0.792-0.942)   0.001      0.953 (0.891-1.020)   0.164      0.952 (0.878-1.031)   0.227
  Marital status                                                                                                                               
  Married             Reference                        Reference                        Reference                        Reference             
  Others              1.326 (1.272-1.383)   \< 0.001   1.142 (1.086-1.201)   \< 0.001   1.212 (1.165-1.262)   \< 0.001   1.078 (1.026-1.132)   0.003
  Primary site                                                                                                                                 
  Colon               Reference                        Reference                        Reference                        Reference             
  Rectum              0.799 (0.758-0.841)   \< 0.001   0.759 (0.711-0.811)   \< 0.001   0.839 (0.797-0.882)   \< 0.001   0.779 (0.731-0.830)   \< 0.001
  Grade                                                                                                                                        
  I + II              Reference                        Reference                        Reference                        Reference             
  III + IV            1.530 (1.450-1.614)   \< 0.001   1.580 (1.484-1.682)   \< 0.001   1.447 (1.375-1.523)   \< 0.001   1.506 (1.417-1.601)   \< 0.001
  Others              1.702 (1.614-1.795)   \< 0.001   1.149 (1.074-1.228)   \< 0.001   1.544 (1.473-1.619)   \< 0.001   1.178 (1.109-1.251)   \< 0.001
  Surgery                                                                                                                                      
  Yes                 Reference                        Reference                        Reference                        Reference             
  No                  1.953 (1.859-2.051)   \< 0.001   2.133 (2.011-2.262)   \< 0.001   1.632 (1.552-1.716)   \< 0.001   1.955 (1.843-2.074)   \< 0.001
  Chemotherapy                                                                                                                                 
  Yes                 Reference                        Reference                        Reference                        Reference             
  No/unknown          2.520 (2.395-2.651)   \< 0.001   2.282 (2.164-2.405)   \< 0.001   2.558 (2.430-2.692)   \< 0.001   2.565 (2.432-2.705)   \< 0.001
  Radiotherapy                                                                                                                                 
  Yes                 Reference                        Reference                        Reference                        Reference             
  No                  2.337 (2.069-2.639)   \< 0.001   1.236 (1.085-1.408)   0.001      1.695 (1.465-1.961)   \< 0.001   0.946 (0.813-1.101)   0.472

HR: Hazard ratio; CI: Confidence interval.

After PSM adjustment, we obtained 3732 and 3568 matched patients in the M1a and M1b groups, respectively. Their survival curves were plotted by the Kaplan-Meier method (Figure [1A](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}). Patients receiving palliative primary tumor resection had longer survival time than those without surgery (*P* \< 0.001). For patients with M1a diseases, palliative resection could increase the median survival time by 9 mo; for patients with M1b diseases, palliative resection can prolong the median survival time by 7 mo (Table [3](#T3){ref-type="table"}). Then M1a diseases were further subdivided by metastatic site. Patients with liver metastasis and lung metastasis were included in the further analysis, whereas patients with bone metastasis and brain metastasis were excluded because of small sample size. As shown in Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}, patients with lung metastasis could obtain more clinical benefit from palliative resection than those with liver metastasis (15 mo for lung metastasis *vs* 8 mo for liver metastasis, Table [3](#T3){ref-type="table"}, *P* \< 0.001).

![Survival time for metastatic colorectal adenocarcinoma patients with or without palliative primary tumor resection. A: Total patients with M1a diseases; B: Patients with M1a diseases (liver metastasis); C: Patients with M1a diseases (lung metastasis); D: Patients with M1b diseases.](WJCC-8-3230-g001){#F1}

###### 

Survival time for metastatic colorectal adenocarcinoma patients with or without palliative primary tumor resection

                           **Median survival time (95%CI)**   **1-yr survival rate (%)**   **3-yr survival rate (%)**
  ------------------------ ---------------------------------- ---------------------------- ----------------------------
  M1a (total)                                                                              
  No surgery               14 (13.275-14.725)                 54.4                         13.9
  Surgery                  23 (21.977-24.023)                 70.4                         32.6
  M1a (liver metastasis)                                                                   
  No surgery               14 (13.320-14.780)                 53.8                         13.4
  Surgery                  22 (20.955-23.045)                 69.2                         29.8
  M1a (lung metastasis)                                                                    
  No surgery               18 (15.692-20.308)                 62.2                         18.6
  Surgery                  33 (28.014-37.986)                 77.5                         45.4
  M1b                                                                                      
  No surgery               10 (9.401-10.599)                  42.2                         8.6
  Surgery                  17 (16.209-17.791)                 60.0                         20.4

DISCUSSION
==========

Metastatic CRC is a lethal disease with a poor prognosis. While patients with metastatic CRC can obtain clinical benefits from curative surgery, there is still controversy with respect to the role of palliative primary tumor resection. To the best of our knowledge, this is the first population-based study subdividing stage IV into stages IVA (M1a diseases) and IVB (M1b diseases) to evaluate the effect of palliative primary tumor resection. It was determined that patients with M1a diseases could obtain more survival benefits than those with M1b diseases and patients with M1a (lung metastasis) got best long-term outcomes with median OS prolonged by 15 mo compared with those without surgical treatment. These findings provided further evidence to support palliative surgical procedure to metastatic CRA and develop effective individualized treatment strategy.

There were many predictors of OS in patients with unresectable metastatic CRC, including WHO PS, carcinoembryonic antigen level, number of metastatic sites, and palliative surgery\[[@B13]\]. Li et al\[[@B17]\] showed that tumor location (right colon *vs* left colon *vs* rectum) was also an independent prognostic factor for metastatic CRC. The results were in line with our findings that patients with rectal cancer were at a lower risk of death than those with colon cancer, possibly owing to higher proportion of lung metastasis in patients with rectal cancer\[[@B18]\]. However, no studies focus on the effect of palliative surgery according to the number of metastatic sites or organs (M1a or M1b). Tarantino et al\[[@B14]\] reported that the survival difference between patients with palliative resection and those without palliative resection was anticipated to decrease due to the development of chemotherapeutic and molecule-targeted drugs. Actually, the significance of survival difference has persisted over time. This may be explained by the heterogeneity of stage IVA (M1a diseases) and stage IVB (M1b diseases). The development of systemic treatment could decrease the survival difference and increase surgery conversion indeed. The proportion of M1b diseases grew from 48.6% during 2010-2012 to 51.6% during 2013-2015 (Table [1](#T1){ref-type="table"}, *P* \< 0.001) and such patients were less likely to undergo surgical treatment than those with M1a diseases. This may also explain the decreased rate of patients undergoing primary tumor removal observed during 1998-2009 in Tarantino's study\[[@B14]\].

Liver and lung metastases are the most two common distant metastases from CRC\[[@B7]\], accounting for 50% and 10%-15% of CRC, respectively\[[@B19],[@B20]\]. The prognosis of patients with liver or lung metastasis is usually better than those with brain or bone metastasis\[[@B21]\]. According to the published literature, median OS was 3-6 mo for patients with brain metastases and 5-7 mo for those with bone metastases\[[@B22]-[@B28]\]. For patients with unresectable liver metastases who were treated with chemotherapy only, median OS was approximately 20 mo\[[@B29]\]. By comparison, patients with unresectable lung metastases, who achieved a complete or partial response to chemotherapy, could achieve a median OS of 27 mo\[[@B30]\]. From the perspective of epidemiology, the median time between the diagnosis of CRC and the emergence of liver metastases was shorter than that for lung metastases (17.2 mo for liver *vs* 24.6 mo for lung)\[[@B31]\], which indicated that liver metastases possessed more aggressive malignant behavior to some extent. These survival findings were similar to the present results (22 mo for liver metastasis with palliative surgery *vs* 33 mo for lung metastasis with palliative surgery).

There are several limitations to this study that should be noted. PSM can adjust potential confounding variables and decrease selection bias as much as possible, increasing precision by creating a 'quasi-randomized' experiment\[[@B32]\]. However, we would like to acknowledge the limitations of our study. First, some significant factors such as surgical complications, life quality, operative tolerance, and laboratory parameters were not included. Second, detailed number of metastases in a single organ was not provided in the SEER database, which hampered further analysis for M1a diseases. Third, further classifications for M1 category in the AJCC staging system were not recorded before 2010, and only patient data between 2010 and 2015 were collected. The conclusions should be validated by more prospective data in the future.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The National Comprehensive Cancer Network clinical practice guidelines do not recommend palliative surgery for metastatic colorectal adenocarcinoma (CRA) unless there is a risk of significant acute bleeding, obstruction, perforation, or another severe symptom.

Research motivation
-------------------

Accumulating evidence has demonstrated that palliative surgery for metastatic CRA patients was associated with more favorable outcomes. However, no studies further classified CRA patients with stage IV into subsets to assess the role of palliative surgery.

Research objectives
-------------------

The purpose of this study was to investigate the separate role of palliative primary tumor resection for CRA patients with stage IVA (M1a diseases) and stage IVB (M1b diseases).

Research methods
----------------

CRA patient records with definite M1a and M1b categories were analyzed by adjusted propensity score matching. Patient prognosis was assessed by univariate and multivariate Cox regression analyses with hazard ratios and 95% confidence intervals.

Research results
----------------

Patients with metastatic CRA receiving palliative primary tumor resection had a longer survival time than those who did not (*P* \< 0.001). Palliative resection increased the median survival time by 9 mo and by 7 mo for patients with M1a and M1b diseases, respectively. For M1a diseases, patients with lung metastasis had more survival benefit from palliative resection than those with liver metastasis (15 mo for lung metastasis *vs* 8 mo for liver metastasis, *P* \< 0.001).

Research conclusions
--------------------

Palliative primary tumor resection improves survival for all CRA patients but more beneficial for those with M1a diseases than those with M1b diseases. Specifically, patients with M1a (lung metastasis) had the best long-term outcomes after palliative primary tumor resection.

Research perspectives
---------------------

These findings provided further evidence to support the use of palliative surgical procedures to treat metastatic CRA and develop effective individualized treatment strategies.

Institutional review board statement: The study was approved by the Bioethics Committee of the Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, China.

Informed consent statement: All patients from the SEER database have agreed to participate in scientific research.

Conflict-of-interest statement: All authors declare no competing financial interests.

Manuscript source: Unsolicited manuscript

Peer-review started: January 14, 2020

First decision: April 12, 2020

Article in press: June 29, 2020

Specialty type: Medicine, research and experimental

Country/Territory of origin: China

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Akbulut S, Lee CL, Nakano H S-Editor: Dou Y L-Editor: Wang TQ E-Editor: Li JH

Data sharing statement
======================

No additional data are available.

[^1]: Author contributions: Li CL and Zhao JQ designed the research and critically revised the manuscript for important intellectual content; all authors performed the research, analyzed the data, and wrote the paper.

    Corresponding author: Jian-Qiang Zhao, MD, Doctor, Department of Thoracic Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, No. 1 West Huanghe Road, Huaian 223300, Jiangsu Province, China. <shenglee6871@sina.com>
